Additional file 4: Figure S2. of Cancer network activity associated with therapeutic response and synergism
Jordi Serra-Musach(Bellvitge University Hospital), Miquel Angel Pujana, Samira Jaeger(Institute for Research in Biomedicine), Álex Cordero(Institut d'Investigació Biomédica de Bellvitge), Raj Guha(National Institutes of Health), Eva Capdevila-Busquets(Universitat Politècnica de Catalunya), Judit Grueso(University of North Carolina at Chapel Hill), Mikael Benson(Karolinska Institutet), Miguel Vizoso(Institut d'Investigació Biomédica de Bellvitge), Francesca Mateo(Institut d'Investigació Biomédica de Bellvitge), Violeta Serra(Vall d'Hebron Institute of Oncology), Joaquı́n Arribas(Hospital Del Mar), Andreas Tjärnberg(Linköping University), Marc Ferrer, Manel Esteller, Eva Gonzalez-Suarez, Gema Moreno-Bueno, Xiaohu Zhang, Patrick Aloy, Holger Heyn, Gorka de Garibay, Craig Thomas, Conxi Lazaro, Mika Gustafsson(Linköping University), Hector Pérez, Alberto Villanueva(Institut d'Investigació Biomédica de Bellvitge)
Cited by 0
Related Papers
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
|Cancer Discovery|2012|622
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
|Oncogene|2011|534
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
|Annals of Oncology|2020|478
Digital twins to personalize medicine
|Genome Medicine|2019|475
Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells
|Journal of Clinical Investigation|2012|462